An open label, multi-centre, post marketing surveillance (PMS) to monitor the safety and effectiveness of INCRUSE administered in Korean subjects with chronic obstructive pulmonary disease (COPD) in usual practice

Trial description: INCRUSE (umeclidinium bromide) is a long-acting muscarinic receptor antagonist in development as an orally inhaled product for the treatment of COPD. Its use was approved on the 25th of June 2015 in Korea. The current study is a post marketing surveillance to monitor its safety and efficacy based on the data collected in a ‘real-world’ clinical practice.The primary objective of this study is to monitor adverse events; the secondary objective is to monitor efficacy. Subjects will use the INCRUSE as per their prescription, in an open-label manner. This study is observational in nature, and will not alter the subject’s prescription or standard of care. The investigator will follow-up at least once with each subject, after the subject has received at least one dose of INCRUSE, for the safety evaluation. Efficacy will be assessed by a 24-week follow-up. Each subject will be monitored for a maximum of 6 months.INCRUSE is a registered trademark of the GlaxoSmithKline Group of Companies.